Genyro

Genyro is pleased to share a new publication in #NatureBiotechnology from co-founder Brian Hie and his colleagues Stanford University titled “Efficient Generation of Epitope-Targeted Antibodies with Germinal.” Full paper: nature.com/articles/s4158…

Genyro’s co-founder and CEO Adrian Woolfson participated in the #FutureTrendsForum in Madrid last week, which explored the future of synthetic biology and how nations can position themselves at the forefront of this transformation.

We pleased to announce a new pre-print, just deposited in BioRxiv and medRxiv tited “Rapid in vitro synthesis of DNA templates via Sidewinder for polyadenylated Hantavirus mRNA vaccine candidates.” Find the pre-print here: doi.org/10.64898/2026.…

We are pleased to announce a new preprint published in BioRxiv. By using new design algorithm, #PyWinder, #Sidewinder utilizes single oligo pools to assemble 640 oligos in parallel with an unprecedented misconnection rate of 1 in 10,000,000. Preprint: tinyurl.com/ymefkw8n

@Genyroinc CEO @AdrianWoolfson is happy to announce that the company he founded prior to @Genryo, @replaybio, has been acquired by @LEOHealthySkin for USD 50 million upfront, plus milestone payments, and tiered royalties.

Building biology at the rate of design.